AIM – A Decade of Achievement Hardman & Co Monthly

Hardman & Co

Hardman & Co Report Report DownloadsIn the November edition of the Hardman Monthly Newsletter, Nigel Hawkins assesses the achievements of AIM – and how it has thrived, despite a challenging financial environment, in recent years.

► AIM, which was founded in 1995, now hosts 959 stocks, currently worth over £100 billion.

► Since its founding, over £100 billion has been raised by AIM-quoted stocks – with 2006 and 2007 being its best years.

► The AIM Index has risen by 31% over the last year and by over 60% during the last five years. Impressive.

► AIM now hosts eleven companies with valuations of over £1 billion each, led by top on-line clothing retailer ASOS, currently worth c£5 billion.

► Liquidity on AIM has improved remarkably in recent years – Read Keith Hiscock’s article: Liquidity – little understood, even before MIFID II.

Share on:

Latest Company News

IBM-SLA breach strengthens the case for data-level encryption

The IBM-SLA breach shows why organisations may need to protect sensitive information directly, keeping it encrypted even when systems or accounts are compromised.

Time Finance adds experienced manager to support invoice finance clients

Time Finance has expanded its invoice finance team with an experienced relationship manager covering clients primarily across the Midlands.

RM Technology expands UK schools offering through Digital Poverty Alliance Partnership

RM Technology has partnered with the Digital Poverty Alliance to help UK schools fund and deliver one-to-one student device programmes.

Markets face a new test from rates, oil and AI valuations

Markets enter the second half of 2026 facing higher rate expectations, renewed oil risks and a tougher test for AI-related valuations.

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Verici Dx adds senior transplant experts to support clinical development

Verici Dx has expanded its Scientific Advisory Board with 14 senior transplant and clinical research specialists to support product development and adoption.

    Search